Elevated Plasma Soluble Lectin-like Oxidised Low-density Lipoprotein Receptor 1 As an Independent Prognostic Biomarker in Sepsis

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2025 Feb 13

PMID 39948564

Authors

Patricia Mester

Charlotte Birner

Stephan Schmid

Martina Muller

Vlad Pavel

Christa Buechler

Affiliations

Soon will be listed here.

Abstract

Background: Soluble lectin-like oxidised low-density lipoprotein receptor 1 (sLOX-1) is overproduced during inflammation, with its expression and release triggered by C-reactive protein (CRP). As CRP levels are typically elevated in sepsis, this study aimed to investigate whether sLOX-1 levels increase in parallel.

Methods: Plasma sLOX-1 levels of 52 patients with systemic inflammatory response syndrome (SIRS), 45 patients with sepsis, 88 patients with septic shock and 37 controls were measured by ELISA. Associations with CRP, underlying diseases, severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and bacterial infections were analysed.

Results: Plasma sLOX-1 levels were similarly elevated in patients with SIRS, sepsis, or septic shock compared to controls. Plasma sLOX-1 levels did not differ between male and female controls or patients. Plasma sLOX-1 levels were comparable in patients infected with SARS-CoV-2, Gram-negative bacteria, or Gram-positive bacteria. No association was observed between sLOX-1 levels and underlying liver cirrhosis or pancreatitis. Notably, plasma sLOX-1 levels correlated positively with leukocyte and basophil counts but showed no correlation with CRP or procalcitonin. Of clinical relevance, positive correlations were also found with aspartate aminotransferase (AST) and bilirubin levels. Among the 41 patients who did not survive, sLOX-1, AST, and bilirubin levels were significantly higher compared to those of survivors.

Conclusions: Plasma levels of sLOX-1 are elevated in patients with SIRS or sepsis and are significantly higher in non-survivors. Of note, they do not correlate with classical inflammatory markers, suggesting that sLOX-1 may function as an independent prognostic biomarker for predicting poor outcomes in patients with SIRS or sepsis.

References

Umemura Y, Ogura H, Takuma K, Fujishima S, Abe T, Kushimoto S . Current spectrum of causative pathogens in sepsis: A prospective nationwide cohort study in Japan. Int J Infect Dis. 2020; 103:343-351. DOI: 10.1016/j.ijid.2020.11.168. View

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kita T . Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome--a pilot study. Circ J. 2010; 74(7):1399-404. DOI: 10.1253/circj.cj-09-0924. View

Huerta L, Rice T . Pathologic Difference between Sepsis and Bloodstream Infections. J Appl Lab Med. 2019; 3(4):654-663. DOI: 10.1373/jalm.2018.026245. View

Wang Z, Guo X, Zhang Q, Du G, Zeng Z, Zheng C . Elimination of Ox-LDL through the liver inhibits advanced atherosclerotic plaque progression. Int J Med Sci. 2021; 18(16):3652-3664. PMC: 8579296. DOI: 10.7150/ijms.63065. View

Pieri G, Agarwal B, Burroughs A . C-reactive protein and bacterial infection in cirrhosis. Ann Gastroenterol. 2014; 27(2):113-120. PMC: 3982625. View

Navarra T, Del Turco S, Berti S, Basta G . The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: cardiovascular implications. J Atheroscler Thromb. 2009; 17(4):317-31. DOI: 10.5551/jat.3228. View

Taylor R, Zhang C, George D, Kotecha S, Abdelghaffar M, Forster T . Low circulatory levels of total cholesterol, HDL-C and LDL-C are associated with death of patients with sepsis and critical illness: systematic review, meta-analysis, and perspective of observational studies. EBioMedicine. 2024; 100:104981. PMC: 10844818. DOI: 10.1016/j.ebiom.2024.104981. View

Pierrakos C, Velissaris D, Bisdorff M, Marshall J, Vincent J . Biomarkers of sepsis: time for a reappraisal. Crit Care. 2020; 24(1):287. PMC: 7273821. DOI: 10.1186/s13054-020-02993-5. View

10.

Plebani M . Why C-reactive protein is one of the most requested tests in clinical laboratories?. Clin Chem Lab Med. 2023; 61(9):1540-1545. DOI: 10.1515/cclm-2023-0086. View

11.

Behnes M, Brueckmann M, Liebe V, Liebetrau C, Lang S, Putensen C . Levels of oxidized low-density lipoproteins are increased in patients with severe sepsis. J Crit Care. 2008; 23(4):537-41. DOI: 10.1016/j.jcrc.2008.09.002. View

12.

Tan K, Shiu S, Wong Y, Leng L, Bucala R . Soluble lectin-like oxidized low density lipoprotein receptor-1 in type 2 diabetes mellitus. J Lipid Res. 2008; 49(7):1438-44. DOI: 10.1194/jlr.M700551-JLR200. View

13.

Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kominami G, Kita T . Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome--comparison with other biomarkers. J Cardiol. 2010; 56(2):159-65. DOI: 10.1016/j.jjcc.2010.05.002. View

14.

Dhalla N, Temsah R, Netticadan T . Role of oxidative stress in cardiovascular diseases. J Hypertens. 2000; 18(6):655-73. DOI: 10.1097/00004872-200018060-00002. View

15.

Kraler S, Wenzl F, Georgiopoulos G, Obeid S, Liberale L, von Eckardstein A . Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes. Eur Heart J. 2022; 43(19):1849-1860. DOI: 10.1093/eurheartj/ehac143. View

16.

Matarazzo S, Quitadamo M, Mango R, Ciccone S, Novelli G, Biocca S . Cholesterol-lowering drugs inhibit lectin-like oxidized low-density lipoprotein-1 receptor function by membrane raft disruption. Mol Pharmacol. 2012; 82(2):246-54. DOI: 10.1124/mol.112.078915. View

17.

Punzo A, Silla A, Fogacci F, Perillo M, Cicero A, Caliceti C . Bile Acids and Bilirubin Role in Oxidative Stress and Inflammation in Cardiovascular Diseases. Diseases. 2024; 12(5). PMC: 11119340. DOI: 10.3390/diseases12050103. View

18.

Fevery J . Bilirubin in clinical practice: a review. Liver Int. 2008; 28(5):592-605. DOI: 10.1111/j.1478-3231.2008.01716.x. View

19.

Magnasco L, Sepulcri C, Antonello R, Di Bella S, Labate L, Luzzati R . The Role of PCSK9 in Infectious Diseases. Curr Med Chem. 2021; 29(6):1000-1015. DOI: 10.2174/0929867328666210714160343. View

20.

Hofmann A, Brunssen C, Wolk S, Reeps C, Morawietz H . Soluble LOX-1: A Novel Biomarker in Patients With Coronary Artery Disease, Stroke, and Acute Aortic Dissection?. J Am Heart Assoc. 2020; 9(1):e013803. PMC: 6988168. DOI: 10.1161/JAHA.119.013803. View